Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,419
archived clinical trials in
Pulmonary

Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigative Site
873
mi
from 98109
Las Vegas, NV
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigative Site
873
mi
from 98109
Las Vegas, NV
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigative Site
2392
mi
from 98109
Lebanon, NH
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigative Site
2392
mi
from 98109
Lebanon, NH
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigative Site
2440
mi
from 98109
Calabash, NC
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigative Site
2440
mi
from 98109
Calabash, NC
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigative Site
2415
mi
from 98109
Tabor City, NC
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigative Site
2415
mi
from 98109
Tabor City, NC
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigative Site
2010
mi
from 98109
Columbus, OH
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigative Site
2010
mi
from 98109
Columbus, OH
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigative Site
2010
mi
from 98109
Columbus, OH
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigative Site
2010
mi
from 98109
Columbus, OH
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigative Site
1982
mi
from 98109
Marion, OH
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigative Site
1982
mi
from 98109
Marion, OH
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigative Site
2055
mi
from 98109
Zanesville, OH
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigative Site
2055
mi
from 98109
Zanesville, OH
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigative Site
249
mi
from 98109
Eugene, OR
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigative Site
249
mi
from 98109
Eugene, OR
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigative Site
2373
mi
from 98109
Philadelphia, PA
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigative Site
2373
mi
from 98109
Philadelphia, PA
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigative Site
2487
mi
from 98109
Warwick, RI
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigative Site
2487
mi
from 98109
Warwick, RI
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigational Site
2423
mi
from 98109
Charleston, SC
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigational Site
2423
mi
from 98109
Charleston, SC
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigative Site
2322
mi
from 98109
Columbia, SC
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigative Site
2322
mi
from 98109
Columbia, SC
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigative Site
2229
mi
from 98109
Greer, SC
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigative Site
2229
mi
from 98109
Greer, SC
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigative Site
2438
mi
from 98109
N. Myrtle Beach, SC
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigative Site
2438
mi
from 98109
N. Myrtle Beach, SC
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigative Site
1758
mi
from 98109
Boerne, TX
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigative Site
1758
mi
from 98109
Boerne, TX
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigative Site
1375
mi
from 98109
El Paso, TX
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigative Site
1375
mi
from 98109
El Paso, TX
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigative Site
1892
mi
from 98109
Houston, TX
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigative Site
1892
mi
from 98109
Houston, TX
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigative Site
1892
mi
from 98109
Houston, TX
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigative Site
1892
mi
from 98109
Houston, TX
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigative Site
1892
mi
from 98109
Houston, TX
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigative Site
1892
mi
from 98109
Houston, TX
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigative Site
1882
mi
from 98109
Kingwood, TX
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigative Site
1882
mi
from 98109
Kingwood, TX
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis
1786
mi
from 98109
San Antonio, TX
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis
1786
mi
from 98109
San Antonio, TX
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigative Site
2388
mi
from 98109
White River Junction, VT
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigative Site
2388
mi
from 98109
White River Junction, VT
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigative Site
2314
mi
from 98109
Burke, VA
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigative Site
2314
mi
from 98109
Burke, VA
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigative Site
2323
mi
from 98109
Fredericksburg, VA
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigative Site
2323
mi
from 98109
Fredericksburg, VA
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigative Site
2303
mi
from 98109
Manassas, VA
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigative Site
2303
mi
from 98109
Manassas, VA
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigative Site
2351
mi
from 98109
Richmond, VA
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigative Site
2351
mi
from 98109
Richmond, VA
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigative Site
2351
mi
from 98109
Richmond, VA
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigative Site
2351
mi
from 98109
Richmond, VA
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigative Site
1622
mi
from 98109
Oregon, WI
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigative Site
1622
mi
from 98109
Oregon, WI
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigative Site
2229
mi
from 98109
Greenville, SC
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigative Site
2229
mi
from 98109
Greenville, SC
Click here to add this to my saved trials
Exercise Training Study for Patients With Cystic Fibrosis
Self-Regulated Exercise in CF: A Randomized Trial
Status: Enrolling
Updated:  2/18/2016
Antiono J & Janet Palumbo Cystic Fibrosis Center; Children's Hospital of Pittsburgh of UPMC
2134
mi
from 98109
Pittsburgh, PA
Exercise Training Study for Patients With Cystic Fibrosis
Self-Regulated Exercise in CF: A Randomized Trial
Status: Enrolling
Updated: 2/18/2016
Antiono J & Janet Palumbo Cystic Fibrosis Center; Children's Hospital of Pittsburgh of UPMC
2134
mi
from 98109
Pittsburgh, PA
Click here to add this to my saved trials
Vigabatrin for the Treatment of Cocaine Dependency
Vigabatrin for Treatment of Cocaine Dependence: A Phase II Study
Status: Enrolling
Updated:  2/19/2016
Matrix Institute on Addictions
962
mi
from 98109
Los Angeles, CA
Vigabatrin for the Treatment of Cocaine Dependency
Vigabatrin for Treatment of Cocaine Dependence: A Phase II Study
Status: Enrolling
Updated: 2/19/2016
Matrix Institute on Addictions
962
mi
from 98109
Los Angeles, CA
Click here to add this to my saved trials
Vigabatrin for the Treatment of Cocaine Dependency
Vigabatrin for Treatment of Cocaine Dependence: A Phase II Study
Status: Enrolling
Updated:  2/19/2016
Friends Research Institute
975
mi
from 98109
Torrance, CA
Vigabatrin for the Treatment of Cocaine Dependency
Vigabatrin for Treatment of Cocaine Dependence: A Phase II Study
Status: Enrolling
Updated: 2/19/2016
Friends Research Institute
975
mi
from 98109
Torrance, CA
Click here to add this to my saved trials
Vigabatrin for the Treatment of Cocaine Dependency
Vigabatrin for Treatment of Cocaine Dependence: A Phase II Study
Status: Enrolling
Updated:  2/19/2016
VA Medical Center
1020
mi
from 98109
Denver, CO
Vigabatrin for the Treatment of Cocaine Dependency
Vigabatrin for Treatment of Cocaine Dependence: A Phase II Study
Status: Enrolling
Updated: 2/19/2016
VA Medical Center
1020
mi
from 98109
Denver, CO
Click here to add this to my saved trials
Vigabatrin for the Treatment of Cocaine Dependency
Vigabatrin for Treatment of Cocaine Dependence: A Phase II Study
Status: Enrolling
Updated:  2/19/2016
University of Miami School of Medicine
2732
mi
from 98109
Miami, FL
Vigabatrin for the Treatment of Cocaine Dependency
Vigabatrin for Treatment of Cocaine Dependence: A Phase II Study
Status: Enrolling
Updated: 2/19/2016
University of Miami School of Medicine
2732
mi
from 98109
Miami, FL
Click here to add this to my saved trials
Vigabatrin for the Treatment of Cocaine Dependency
Vigabatrin for Treatment of Cocaine Dependence: A Phase II Study
Status: Enrolling
Updated:  2/19/2016
NeuroPsychiatric Research & Practice Assoc., Ltd.
1719
mi
from 98109
Oak Brook, IL
Vigabatrin for the Treatment of Cocaine Dependency
Vigabatrin for Treatment of Cocaine Dependence: A Phase II Study
Status: Enrolling
Updated: 2/19/2016
NeuroPsychiatric Research & Practice Assoc., Ltd.
1719
mi
from 98109
Oak Brook, IL
Click here to add this to my saved trials
Vigabatrin for the Treatment of Cocaine Dependency
Vigabatrin for Treatment of Cocaine Dependence: A Phase II Study
Status: Enrolling
Updated:  2/19/2016
Mountain Manor Treatment Center at Baltimore
2328
mi
from 98109
Baltimore, MD
Vigabatrin for the Treatment of Cocaine Dependency
Vigabatrin for Treatment of Cocaine Dependence: A Phase II Study
Status: Enrolling
Updated: 2/19/2016
Mountain Manor Treatment Center at Baltimore
2328
mi
from 98109
Baltimore, MD
Click here to add this to my saved trials
Vigabatrin for the Treatment of Cocaine Dependency
Vigabatrin for Treatment of Cocaine Dependence: A Phase II Study
Status: Enrolling
Updated:  2/19/2016
Boston University School of Medicine
2485
mi
from 98109
Boston, MA
Vigabatrin for the Treatment of Cocaine Dependency
Vigabatrin for Treatment of Cocaine Dependence: A Phase II Study
Status: Enrolling
Updated: 2/19/2016
Boston University School of Medicine
2485
mi
from 98109
Boston, MA
Click here to add this to my saved trials
Vigabatrin for the Treatment of Cocaine Dependency
Vigabatrin for Treatment of Cocaine Dependence: A Phase II Study
Status: Enrolling
Updated:  2/19/2016
Pacific Institute for Research and Evaluation
1184
mi
from 98109
Albuquerque, NM
Vigabatrin for the Treatment of Cocaine Dependency
Vigabatrin for Treatment of Cocaine Dependence: A Phase II Study
Status: Enrolling
Updated: 2/19/2016
Pacific Institute for Research and Evaluation
1184
mi
from 98109
Albuquerque, NM
Click here to add this to my saved trials
Vigabatrin for the Treatment of Cocaine Dependency
Vigabatrin for Treatment of Cocaine Dependence: A Phase II Study
Status: Enrolling
Updated:  2/19/2016
Western Psychiatric Inst. and Clinic
2134
mi
from 98109
Pittsburgh, PA
Vigabatrin for the Treatment of Cocaine Dependency
Vigabatrin for Treatment of Cocaine Dependence: A Phase II Study
Status: Enrolling
Updated: 2/19/2016
Western Psychiatric Inst. and Clinic
2134
mi
from 98109
Pittsburgh, PA
Click here to add this to my saved trials
Vigabatrin for the Treatment of Cocaine Dependency
Vigabatrin for Treatment of Cocaine Dependence: A Phase II Study
Status: Enrolling
Updated:  2/19/2016
Medical University of South Carolina
2422
mi
from 98109
Charleston, SC
Vigabatrin for the Treatment of Cocaine Dependency
Vigabatrin for Treatment of Cocaine Dependence: A Phase II Study
Status: Enrolling
Updated: 2/19/2016
Medical University of South Carolina
2422
mi
from 98109
Charleston, SC
Click here to add this to my saved trials
Vigabatrin for the Treatment of Cocaine Dependency
Vigabatrin for Treatment of Cocaine Dependence: A Phase II Study
Status: Enrolling
Updated:  2/19/2016
Pillar Clinical Research, LLC
1676
mi
from 98109
Dallas, TX
Vigabatrin for the Treatment of Cocaine Dependency
Vigabatrin for Treatment of Cocaine Dependence: A Phase II Study
Status: Enrolling
Updated: 2/19/2016
Pillar Clinical Research, LLC
1676
mi
from 98109
Dallas, TX
Click here to add this to my saved trials
Vigabatrin for the Treatment of Cocaine Dependency
Vigabatrin for Treatment of Cocaine Dependence: A Phase II Study
Status: Enrolling
Updated:  2/19/2016
University of Texas Health Science Center at Houston
1884
mi
from 98109
Houston, TX
Vigabatrin for the Treatment of Cocaine Dependency
Vigabatrin for Treatment of Cocaine Dependence: A Phase II Study
Status: Enrolling
Updated: 2/19/2016
University of Texas Health Science Center at Houston
1884
mi
from 98109
Houston, TX
Click here to add this to my saved trials
Vigabatrin for the Treatment of Cocaine Dependency
Vigabatrin for Treatment of Cocaine Dependence: A Phase II Study
Status: Enrolling
Updated:  2/19/2016
George E. Wahlen VA Medical Center
701
mi
from 98109
Salt Lake City, UT
Vigabatrin for the Treatment of Cocaine Dependency
Vigabatrin for Treatment of Cocaine Dependence: A Phase II Study
Status: Enrolling
Updated: 2/19/2016
George E. Wahlen VA Medical Center
701
mi
from 98109
Salt Lake City, UT
Click here to add this to my saved trials
Assessment of an Endotracheal Tube Securement Device
Assessment of the Functionality and Performance of an Endotracheal (ET) Tube Protection Device
Status: Enrolling
Updated:  2/23/2016
The Hartford Hospital
2429
mi
from 98109
Hartford, CT
Assessment of an Endotracheal Tube Securement Device
Assessment of the Functionality and Performance of an Endotracheal (ET) Tube Protection Device
Status: Enrolling
Updated: 2/23/2016
The Hartford Hospital
2429
mi
from 98109
Hartford, CT
Click here to add this to my saved trials
Assessment of an Endotracheal Tube Securement Device
Assessment of the Functionality and Performance of an Endotracheal (ET) Tube Protection Device
Status: Enrolling
Updated:  2/23/2016
MedStar Washington Hospital Center
2322
mi
from 98109
Washington,
Assessment of an Endotracheal Tube Securement Device
Assessment of the Functionality and Performance of an Endotracheal (ET) Tube Protection Device
Status: Enrolling
Updated: 2/23/2016
MedStar Washington Hospital Center
2322
mi
from 98109
Washington,
Click here to add this to my saved trials
Assessment of an Endotracheal Tube Securement Device
Assessment of the Functionality and Performance of an Endotracheal (ET) Tube Protection Device
Status: Enrolling
Updated:  2/23/2016
St. Joseph's Hospitals
2524
mi
from 98109
Tampa, FL
Assessment of an Endotracheal Tube Securement Device
Assessment of the Functionality and Performance of an Endotracheal (ET) Tube Protection Device
Status: Enrolling
Updated: 2/23/2016
St. Joseph's Hospitals
2524
mi
from 98109
Tampa, FL
Click here to add this to my saved trials
Assessment of an Endotracheal Tube Securement Device
Assessment of the Functionality and Performance of an Endotracheal (ET) Tube Protection Device
Status: Enrolling
Updated:  2/23/2016
Legacy Good Samaritan
146
mi
from 98109
Portland, OR
Assessment of an Endotracheal Tube Securement Device
Assessment of the Functionality and Performance of an Endotracheal (ET) Tube Protection Device
Status: Enrolling
Updated: 2/23/2016
Legacy Good Samaritan
146
mi
from 98109
Portland, OR
Click here to add this to my saved trials
Assessment of an Endotracheal Tube Securement Device
Assessment of the Functionality and Performance of an Endotracheal (ET) Tube Protection Device
Status: Enrolling
Updated:  2/23/2016
Legacy Salmon Creek Medical Center
133
mi
from 98109
Vancouver, WA
Assessment of an Endotracheal Tube Securement Device
Assessment of the Functionality and Performance of an Endotracheal (ET) Tube Protection Device
Status: Enrolling
Updated: 2/23/2016
Legacy Salmon Creek Medical Center
133
mi
from 98109
Vancouver, WA
Click here to add this to my saved trials
Inhaled Fluticasone Effects on Upper Airway Patency in Obstructive Lung Disease
Inhaled Fluticasone Effects on Upper Airway Patency in Obstructive Lung Disease
Status: Enrolling
Updated:  2/24/2016
William S. Middleton Memorial Veterans Hospital, Madison, WI
1617
mi
from 98109
Madison, WI
Inhaled Fluticasone Effects on Upper Airway Patency in Obstructive Lung Disease
Inhaled Fluticasone Effects on Upper Airway Patency in Obstructive Lung Disease
Status: Enrolling
Updated: 2/24/2016
William S. Middleton Memorial Veterans Hospital, Madison, WI
1617
mi
from 98109
Madison, WI
Click here to add this to my saved trials